A twice-a-year injectable drug has been shown to be 100% effective in preventing the spread of HIV, according to the first data from a clinical trial. If approved, the drug offers another preventive ...

The U.S. Food and Drug Administration has approved a highly effective HIV prevention drug that outperforms oral medications in stopping HIV transmission. Developed by Gilead Sciences, the drug ...

Dallas resident Clint Hassell comes to the Fort Worth location of the HELP Center for LGBT Health & Wellness for free PrEP services. He started taking the PrEP medicine around two years to reduce the ...

US Sen. Kamala Harris is introducing a bill to reduce the transmission of HIV by encouraging the use of PrEP, or pre-exposure prophylaxis, a drug that's more than 92% effective in preventing new ...

Bisexual men encounter unique sexual health risks due to their sexual relationships with both men and women. This dual-risk exposure can sometimes lead to higher rates of STIs, including HIV, herpes, ...

When Nicklaus Chalk started law school at the University of California, Berkeley, last fall, one of his top priorities was to take care of his health. The 24-year-old student visited a doctor to get a ...

It’s been over a decade since the Food and Drug Administration first approved a medication to prevent HIV. But the Centers for Disease Control and Prevention estimates just 30% of the 1.2 million ...

The Centers for Medicare & Medicaid Services (CMS) is recommending preexposure prophylaxis (PrEP) with oral or injectable antiretroviral therapy to people at risk of HIV without patient cost sharing.

This is a KFF Health News story. A proposed federal policy aims to protect older Americans from contracting HIV by offering free preventive medication, the latest effort to catch up to much of Europe ...

HIV rates are up in Atlanta. Activists and Georgia politicians say this doesn’t have to happen because cheap and safe medicines known as PrEP are over 99% effective at blocking the infection when ...

In June, Gilead Sciences announced impressive early results from its PURPOSE 1 trial, which showed 100 percent efficacy of lenacapavir in preventing new HIV infections among cisgender women in ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Carl Schmid and ...